Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia.

Abstract

Our data confirm that bortezomib, like other proteasome inhibitors, has proapoptotic activity in CLL cells.